Streit A, Furlan M, Beck E A
Schweiz Med Wochenschr. 1984 Oct 6;114(40):1389-91.
To permit home treatment in our patients we investigated the response to intranasal administration of 260 micrograms DDAVP in 28 patients with either mild hemophilia A or von Willebrand's disease. 6 patients with mild hemophilia A responded, and 6 did not. In the group with von Willebrand's disease 6 responded well, 4 responded partially and 6 did not respond. Knowledge of the severity of the disease did not allow us to predict the response, and therefore every patient should be tested individually. Intranasal DDAVP in our patients was used with success for bleeding into the knee joint, muscle hematoma and hematuria.
为了让我们的患者能够在家中接受治疗,我们对28例轻度甲型血友病或血管性血友病患者鼻内给予260微克去氨加压素的反应进行了研究。6例轻度甲型血友病患者有反应,6例无反应。在血管性血友病组中,6例反应良好,4例部分反应,6例无反应。对疾病严重程度的了解无法让我们预测反应情况,因此每个患者都应单独进行检测。我们的患者使用鼻内去氨加压素成功治疗了膝关节出血、肌肉血肿和血尿。